Imunosuppresants Flashcards
Alemtuzumab target use and notes
CD52
CLL, MS
Bevacizumab
Target: VEGF
Use: Colorectal cancer, renal cell carcinoma, non-small cell lung cancer
Cetuximab
EGFR
Stage IV colorectal cancer, head and neck
Rituximab
CD20
B cell non-Hodgkin lymphoma, CLL, rheumatoid arthritis, ITP
Tastuzumab
HER2/Neu
Breast cancer, gastric cancer
Adalimumab, certolizumab, golimumab
Soluble TNF-alpha
IBD, rheumatoid arthritis, ankylosis spondylitis, psoriasis
Daclizumab
CD25
Relapsing MS
Eculizumab
Complement protein C5
Paroxysmal nocturnal hemoglobinuria
Natalizumab
Alpha4 interin
MS, crohn disease
Ustekinumab
IL12/IL23
Psoriasis, psoriatic arthritis
Bevacizumab
Antibody against VEGF
Used for solid tumors (colorectal cancer, RCC)
AE: Hemorrhage, blood clots, impaired wound healing
Erlotinib
Mech: EGFR tyrosine kinase inhibitor
Use: Non small cell lung carcinoma
AE: rash
Cetuximab
Use: Anti EGFR
Use: IV colorectal cancer, head and neck
AE: Rash, LFTs, diarrhea
Imatinib
Mech: Tyrosine kinase inhibitor of BCL-ABL and cKIT
Use: CML, GI Stromal tumors
AE: Fluid retention
Rituximab
Monoclonal antibody against CD20
Nonhodgkin lymphoma, CLL, ITP, rheumatoid arthritis
AE: Increased risk of progressive multi focal leukoencephalopathy